MEDESIS PHARMA S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.245 EUR | +0.40% |
|
-18.09% | +43.43% |
| 2023 | Medesis Pharma S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| 2023 | MEDESIS : Invest Securities confirms its recommendation | CF |
| Sales 2021 | 95.73K 103K 8.57M | Sales 2022 | 197K 212K 17.66M | Capitalization | 8.68M 9.3M 777M |
|---|---|---|---|---|---|
| Net income 2021 | -2M -2.15M -179M | Net income 2022 | -2M -2.15M -179M | EV / Sales 2021 | 219 x |
| Net cash position 2021 | 1.61M 1.72M 144M | Net Debt 2022 | 1.08M 1.15M 96.3M | EV / Sales 2022 | 49.4 x |
| P/E ratio 2021 |
-8.52
x | P/E ratio 2022 |
-3.16
x | Employees | 10 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 80.97% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +0.40% | ||
| 1 week | -18.09% | ||
| Current month | -18.36% | ||
| 1 month | -20.45% | ||
| 3 months | +52.20% | ||
| 6 months | +47.51% | ||
| Current year | +43.43% |
1 week
1.24
1.53
1 month
1.241.58
Current year
0.752.40
1 year
0.752.67
3 years
0.7510.10
5 years
0.7518.00
10 years
0.7518.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 03/03/03 | |
Solene Guilliot
CTO | Chief Tech/Sci/R&D Officer | - | 01/21/01 |
Mario Alcaraz
SEC | Corporate Secretary | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | 12/19/12 | |
Robert Alonso
BRD | Director/Board Member | - | 27/22/27 |
Walt Linscott
BRD | Director/Board Member | 63 | 27/22/27 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/24/02 | 1.245 | +0.40% | 232 |
| 30/24/30 | 1.24 | -6.77% | 4,522 |
| 29/24/29 | 1.33 | -5.00% | 3,094 |
| 26/24/26 | 1.4 | -2.10% | 2,682 |
| 25/24/25 | 1.43 | -5.92% | 668 |
Real-time Euronext Paris, May 02, 2024 at 04:09 pm IST
More quotes
Medesis Pharma S.A. is specialized in the research and development, based on a breakthrough technology (AONYS®) for the delivery of therapeutic molecules, of drugs to treat diseases for which there is no effective treatment.
The company's portfolio includes a drug candidate used to optimize cancer radiotherapy, 2 drug candidates used in the treatment of neurodegenerative diseases (Alzheimer's disease and Huntington's disease) and 2 drug candidates used in the treatment of radioactive contamination following a civil or military nuclear accident (Plutonium decorporation and cesium decorporation).
| 1st Jan change | Capi. | |
|---|---|---|
| +43.43% | 5.87M | |
| -1.93% | 104B | |
| +6.84% | 97.47B | |
| +5.71% | 22.25B | |
| -12.67% | 21.68B | |
| -9.70% | 18.2B | |
| -39.98% | 17.02B | |
| -10.63% | 16.36B | |
| +6.94% | 14.39B | |
| +36.13% | 12.37B |
- Stock Market
- Equities
- ALMDP Stock
